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Discussion

Case Presentation

At this time, the patient had four biopsy proven KAs on the right forearm in the area of prior radiation (figure 1). The patient was treated with topical 5-Fluorouracil (5-FU) 5%
cream twice daily for 4 weeks, applied to the right arm from the elbow to the wrist and occluded under an elastic bandage. The patient stated that the biopsy sites became
sore and inflamed during the treatment. After 4 weeks of treatment, 2 of the KA biopsy sites had healed without clinical evidence of tumor. The other two biopsy sites had
developed adjacent firm pink papules (Figure 2). These 2 lesions were then treated with intralesional (IL) 5-FU injectable 50mg/ml once weekly to resolution at 4 and 5 weeks
respectively. The proximal lesion was treated with 7.5mg on week 1 and 5mg on weeks 2, 3, and 4. The larger distal lesion was treated with 12.5mg on week 1 and 5mg
on weeks 2, 3, 4, and 5. The volume injected was determined by ability to blanch and indurate the lesion. The volume necessary to achieve this was decreased due to the
shrinking size of the tumor. After three injections, both tumors had decreased in size substantially (figure 3). At the end of treatment, both tumors had clinically resolved. These
have not recurred, nor has he developed any new tumors at 9 months after his last injection.

Patient: 78 year-old Caucasian male.
History of Present Illness: Our patient is a 78
year-old male who initially presented in March 2014 with a
papule on his right forearm for 3 months. It was biopsied in March
2014, diagnosed as a well-differentiated invasive squamous cell
carcinoma and subsequently excised with clear margins in April
2014. Squamous cell carcinoma formed two additional times
at the incision and was excised with clear margins. The fourth
squamous cell carcinoma in the area was treated with x-ray
therapy. One month after completion, four papules just adjacent
to the x-ray therapy treatment field were biopsied and diagnosed
as well-differentiated squamous cell carcinoma, keratoacanthoma
(KA) type.
Medical History/Surgical History:
Squamous cell carcinoma, myocardial infarction, diabetes
mellitus II, chronic obstructive pulmonary disease, hypertension,
hypercholesterolemia, gout, diverticulosis
Medications: Finasteride, metoprolol tartrate,
allopurinol, atorvastatin, furosemide, brimonidine ophthalmic,
clopidogrel, travoprost, glimepiride, potassium chloride, losartan,
dexlansoprazole, polyethylene glycol ophthalmic, tacrolimus
ointment, mometasone cream, hydrocodone/acetaminophen,
fluticasone/salmeterol inhaled, aspirin

The concept of “field cancerization” was first proposed in 1953 by Slaughter et al. while studying oral squamous cell carcinoma in an effort to explain the development of
multiple primary tumors and locally recurrent cancer.1,2 Histopathologically, the authors observed: 1) oral cancer develops in multifocal areas of precancerous change, 2)
histologically abnormal hyperplastic tissue surrounds the tumors, 3) oral cancer consists of multiple independent areas that sometimes coalesce, and 4) the persistence of
abnormal tissue after surgery may explain local recurrences and the development of new lesions in a previously treated area.1,2 Since its original publication the concept has
been applied to several other organ systems including the lung, vulva, cervix, breast, bladder, colon and skin.2
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Figure1: Biopsy proven KAs labeled in an area of prior
radiation on the right forearm.
Figure 2: Two firm pink papules adjacent to biopsy proven
KAs remain after 4 weeks of treatment with topical 5-FU
5% cream twice daily for 4 weeks, applied to the right arm
from the elbow to the wrist and occluded under an elastic
bandage.

Physical Examination: Pink patch at radiation site
with healing erosion centrally. Several 5-6 mm pink dermal
papules at periphery of radiation site.

The development of an expanding neoplastic field appears to play an important role in cutaneous carcinogenesis.2,3,4 It is necessary to consider the cutaneous field
cancerization as a highly photodamaged area that contains clinical and subclinical lesions.2,3,4 The treatment of cutaneous neoplasms, squamous cell carcinoma in particular,
should focus not only on the tumor itself, but also on the surrounding tissue.4 Adjunctive field-directed therapies should be considered after treatment of the primary tumor.4
Our patient continued to develop squamous cell carcinomas on the right forearm after multiple excisions with clear margins. He then developed 4 squamous cell carcinomas,
KA type, after radiation therapy to the right forearm. Topical 5-FU is a well-described treatment for field cancerization.2 In our patient, topical 5-FU 5% cream twice daily under
occlusion for 4 weeks led to the involution of 2 out of 4 KAs, and may have prevented the development of new neoplasms for at least 4 months after use. Our patient’s 2
remaining KAs resolved with IL 5-FU weekly for 4 and 5 weeks.

Studies: A CT with contrast of the chest and right upper
extremity did not reveal metastatic disease.

IL 5-FU has been described for the treatment of multiple and difficult to treat KAs. 5-FU is an antimetabolite and structural analog of uracil which disrupts DNA and RNA
synthesis.6 It is contraindicated in liver disease, pregnancy or breast feeding and allergy to the medication.6 IL 5-FU dosing recommendations for KAs include use of a 50mg/
ml solution and injecting 0.1mL to 3mL every 1 to 3 weeks.7 The maximum daily recommended dose is 800mg.6 Recommendations for lab monitoring include a CBC with
differential at baseline and weekly.6 Side effects include local pain, erythema, crusting, ulceration and necrosis.6 Systemic side effects include cytopenias and gastrointestinal
upset.6 IL 5-FU has been used successfully in a single dose of 10mg per lesion in combination with systemic acitretin for the treatment of multiple KAs induced by
vemurafenib.8 It has also been effective in the treatment of multiple recurrent reactive KAs developing in surgical margins.7 A review article reported that the use of IL 5-FU
produced a 98% cure rate in 56 treated KAs.6 Alternative IL agents that may be considered for KAs include methotrexate, bleomycin, and interferon α-2b.6,7
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In the skin, field cancerization involves clusters and contiguous patches of altered cells present in areas of chronic photodamage.2 Genetically altered fields form the foundation
in which multiple clonally related neoplastic lesions can develop.2,3 These fields often remain after treatment of the primary tumor and may lead to new cancers that are
commonly labeled as a second primary tumor or a local recurrence depending on the exact site and time interval.3 Brennan et al. found clonal populations of infiltrating tumor
cells harboring a p53 gene mutation in more than 50% of histopathologically negative surgical margins of patients with squamous cell carcinoma of the head and neck.
Furthermore, 40% of the patients with a margin positive for a p53 gene mutation had local recurrence versus none of the patients with negative margins.4 These findings
are supported by several other studies in which loss of heterozygosity, microsatellite alterations, chromosomal instability or in situ hybridization was used to demonstrate
genetically altered fields.2,4 Histopathologic patterns of epidermolytic hyperkeratosis, focal acantholytic dyskeratosis, and pronounced acantholysis as found in Hailey-Hailey
disease may be a consequence of clonal expansion of mutated keratinocytes because of long-term exposure to mutagens such as UV light and HPV.5
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Figure 3: After three injections with IL 5-FU, both KAs
had decreased in size substantially.

Field cancerization may cause the development of multiple clonally related neoplasms within a field of genetically altered cells. These may continue to develop after excision
with clear margins or radiation therapy. Given the success of treatment in our patient, we recommend consideration for topical and IL 5-FU in patients who develop squamous
cell carcinomas and KAs within an area of field cancerization.
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